China's National Medical Products Administration approved CARsgen Therapeutics' satri-cel for stomach cancer on June 22 — the first time any regulator has greenlit a CAR T-cell therapy for a solid tumor. CAR T has revolutionized blood cancers over the past decade, but solid tumors have resisted every attempt. This approval changes the equation.

Vital Signs

• 600,000 — new bladder cancer cases diagnosed globally each year, a target of parallel CAR T research -...